ISM6200 / Insilico Medicine - LARVOL DELTA

Insilico Medicine nominates ISM6200, a potential best-in-class selective NR3C1 inhibitor for ovarian cancer, Cushing’s Syndrome, hypercortisolism-associated obesity and glaucoma (Eurekalert) - "In a preclinical CDX (cell line-derived xenograft) model, ISM6200 demonstrated significant and dose-dependent enhancement of anti-tumor efficacy when combined with paclitaxel....In the DIO mouse model, ISM6200 demonstrated a good weight loss effect, mainly reducing fat while better retaining muscle mass. After 28 days of administration, compared with the control group, ISM6200 monotherapy achieved significant weight loss, with a relative weight reduction of 8.8% from the baseline....In a rat model of Cushing's syndrome, ISM6200 significantly alleviated insulin resistance and decreased blood pressure."

New molecule • Preclinical • Glaucoma • Obesity • Ovarian Cancer